FDA Approves Radioligand Therapy in PSMA–Positive, Castration-Resistant PC

Fact checked by Russ Conroy
News
Article

Results from PSMAfore show that lutetium Lu 177 vipivotide tetraxetan elicited a median rPFS of 9.3 months vs 5.6 months with ARPI in prostate cancer.

Data from the PSMAfore trial (NCT04689828) supported the expanded indication for lutetium Lu 177 vipivotide tetraxetan.

Data from the PSMAfore trial (NCT04689828) supported the expanded indication for lutetium Lu 177 vipivotide tetraxetan.

The FDA has expanded lutetium Lu 177 vipivotide tetraxetan’s (Pluvicto) indication to include adult patients with prostate-specific membrane antigen (PSMA)–positive, metastatic castration-resistant prostate cancer who received prior androgen receptor pathway inhibitor (ARPI) therapy and are appropriate to delay taxane-based chemotherapy, according to a press release from the FDA.

Supporting data came from the randomized, open-label phase 3 PSMAfore trial (NCT04689828) that enrolled a total of 468 patients who were randomly assigned, in a 1:1 ratio, to receive lutetium Lu 177 vipivotide tetraxetan or a change in ARPI.

The median radiographic progression-free survival (PFS) was 9.3 months (95% CI, 7-not estimable [NE]) with the experimental treatment and 5.6 months (95% CI, 4-6) with ARPI therapy (HR, 0.41; 95% CI, 0.29-0.56; P <.0001). The median overall survival (OS) was 24.5 months (95% CI, 19.5-28.9) vs 23.1 months (95% CI, 19.6-25.5), respectively (HR, 0.91; 95% CI, 0.72-1.14). Also, 60% (n = 114) of patients who were assigned to receive ARPI therapy switched to receive lutetium Lu 177 vipivotide tetraxetan after disease progression.

The safety profile was generally consistent with prior data on lutetium Lu 177 vipivotide tetraxetan, although it was noted that exposure to the treatment may result in risk of renal toxicity, myelosuppression, and radiation exposure.

The recommended dose of lutetium Lu 177 vipivotide tetraxetan is 7.4 GBq (200 mCi) intravenously every 6 weeks for 6 doses. It was also noted that patients should be selected for the agent using the active ingredient gallium Ga 68 gozetotide or another approved PSMA PET product.

Reference

FDA expands Pluvicto’s metastatic castration-resistant prostate cancer indication. News release. FDA. March 28, 2025. Accessed March 28, 2025. https://tinyurl.com/y77tmenc

Recent Videos
Standardizing surgical outcomes and better training oncologic surgeons may be accomplished through the use of AI.
The poly-ICLC trial seeks to develop a delivery mechanism to prostate cancer through different biomarkers.
Ablative technology may generate an immune response that can be enhanced via injected immunotherapy in patients with solid tumors.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Related Content